Log In
BCIQ
Print this Print this
 

Xen2174

  Manage Alerts
Collapse Summary General Information
Company Xenome Ltd.
DescriptionSynthetic conopeptide-based analgesic derived from venom peptide, MrIA
Molecular Target Norepinephrine transporter
Mechanism of ActionNorepinephrine reuptake inhibitor
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I/II
Standard IndicationPain
Indication DetailsTreat chronic pain in cancer patients; Treat post-operative pain; Treat severe cancer pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
Get a free BioCentury trial today